Want to see AU:EXL full AI Analyst Report?
Top Page
Elixinol Wellness
(Sydney:EXL)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.01
â–¼(-30.00% Downside)
Action:Reiterated
Date:09/30/26
The score is primarily driven by weak financial performance: ongoing losses, sharp 2025 margin pressure, and persistent negative operating/free cash flow, alongside some balance sheet deterioration (higher debt and lower equity). Valuation is also constrained by a negative P/E and no provided dividend yield. Technical analysis cannot be assessed with the indicators provided, limiting confidence from a market-trend perspective.
Positive Factors
Revenue Recovery
Revenue has recovered materially from the 2022–2023 base, indicating that the company retains demand for its branded hemp and CBD wellness products. Although 2025 growth turned negative, the higher revenue platform may support future operating improvement if the business can restore margins and control costs.
Negative Factors
Persistent Losses
Recurring negative EBIT and net income show that the business has not yet demonstrated durable profitability across the reported period. Continued losses reduce retained capital, limit internally funded investment, and make the company more dependent on operational improvement or external financing to sustain its strategy.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
Revenue has recovered materially from the 2022–2023 base, indicating that the company retains demand for its branded hemp and CBD wellness products. Although 2025 growth turned negative, the higher revenue platform may support future operating improvement if the business can restore margins and control costs.
Read all positive factors
Elixinol Wellness (EXL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.72M
Dividend YieldN/A
Average Volume (3M)5.59M
Price to Earnings (P/E)―
Beta (1Y)-1.36
Revenue Growth-4.87%
EPS Growth-9.78%
CountryAU
Employees15
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding454,112,180
10 Day Avg. Volume15,329,612
30 Day Avg. Volume5,590,708
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.15
P/FCF Ratio-0.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Elixinol Wellness Business Overview & Revenue Model
Company Description
Elixinol Wellness Limited, an entity established in 2017 and headquartered in Sydney, Australia, operates internationally through its subsidiaries. The company is primarily involved in the manufacturing and global distribution of a wide array of h...
How the Company Makes Money
Elixinol Wellness makes money primarily by selling branded hemp/CBD wellness products to consumers and trade customers. Its core revenue streams are (1) direct-to-consumer sales via company-controlled e-commerce channels, where the company capture...
Elixinol Wellness Earnings Call Summary
Earnings Call Date:Feb 12, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Feb 19, 2027
Earnings Call Sentiment Positive
The call communicated meaningful operational progress: a clear shift to higher-margin channels (e-commerce up to 38%), significant cost structure reduction (~30% in Q4 vs prior year), Q4 profitability and positive operating cash flow, strong D2C momentum (Healthy Chef e-commerce +42% YoY) and product innovation poised to capture market trends. However, challenges remain including modest full-year revenue growth (3.6% YoY), a small absolute revenue base (~$15.5M), supermarket channel pressures for niche SKUs, and regulatory uncertainty in the U.S. CBD business. On balance, the operational improvements and trajectory toward sustainable profitability outweigh the outstanding strategic and market risks, but execution and regulatory clarity will be important near-term drivers.Positive Updates
Q4 Revenue Growth and Strong Exit Run-Rate
Q4 FY25 revenue of $4.1M, up 9.5% quarter-on-quarter, delivering a strong exit run-rate into FY26 and demonstrating seasonal rebound in the business.
Negative Updates
Modest Full-Year Top-Line Growth
FY25 revenue growth was modest at 3.6% year-over-year ($15.5M), indicating limited top-line expansion despite improvements in mix and margins.
Read all updates
Q4-2025 Updates
Positive
Negative
Q4 Revenue Growth and Strong Exit Run-Rate
Q4 FY25 revenue of $4.1M, up 9.5% quarter-on-quarter, delivering a strong exit run-rate into FY26 and demonstrating seasonal rebound in the business.
Read all positive updates
Company Guidance
Management guided FY26 around four pillars — operational momentum, cost efficiency, building a growth foundation and targeted M&A — with the aim of maintaining a structurally lower OpEx run‑rate after cutting the operating cost base by ~30% in Q4 vs Q4 FY24 and delivering Q4 positive EBITDA (slightly better than break‑even) and positive underlying operating cash flow; they completed a two‑tranche $2.5m capital raise and will review capital management at the May AGM. The company will prioritize higher‑margin D2C and e‑commerce (e‑commerce grew from 21% to 38% of revenue in 2025; Healthy Chef e‑commerce +42% YoY in Q4) while reducing low‑margin bulk (from 24% to 14%), leveraging FY25 revenue of $15.5m and a Q4 exit run‑rate of $4.1m (quarterly revenue ranged ~$3–4m) with contracted hemp volumes up for 2026. Management also signalled near‑term actions — pursuing value‑accretive acquisitions, keeping U.S. CBD options open pending regulatory clarity in 2–3 months, and driving product launches (Healthy Chef Metabolic Burn and protein water, plus Mt Elephant NPD into Coles in May) to capture large market opportunities (Australia wellness ~$160bn today to >$300bn by 2033 at ~7% growth, functional foods ~$10.5bn, protein market to $1.1bn by 2034) and narrow the current valuation gap (~0.3x revenue vs peers 1–1.5x).Elixinol Wellness Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
46
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.05M | 15.50M | 14.96M | 8.27M | 7.05M | 9.34M |
| Gross Profit | 1.66M | 752.00K | 5.36M | -1.80M | -3.27M | -6.25M |
| EBITDA | -1.95M | -4.11M | -4.01M | -6.81M | -9.28M | -15.51M |
| Net Income | -3.48M | -5.50M | -1.72M | -7.51M | -10.57M | -17.02M |
Balance Sheet | ||||||
| Total Assets | 15.17M | 15.96M | 18.45M | 11.71M | 13.48M | 25.33M |
| Cash, Cash Equivalents and Short-Term Investments | 996.00K | 1.41M | 1.08M | 708.00K | 2.86M | 12.65M |
| Total Debt | 4.03M | 3.73M | 1.94M | 1.26M | 1.83M | 2.71M |
| Total Liabilities | 8.81M | 8.51M | 8.42M | 5.25M | 4.33M | 6.25M |
| Stockholders Equity | 6.36M | 7.45M | 10.03M | 6.46M | 9.16M | 19.08M |
Cash Flow | ||||||
| Free Cash Flow | -2.62M | -3.28M | -3.53M | -2.77M | -8.16M | -14.36M |
| Operating Cash Flow | -2.54M | -3.21M | -3.47M | -2.76M | -8.15M | -14.07M |
| Investing Cash Flow | -173.00K | -216.00K | -66.00K | -1.04M | -869.00K | 172.00K |
| Financing Cash Flow | 2.52M | 3.65M | 3.92M | 1.61M | -757.00K | -1.16M |
Elixinol Wellness Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$148.18M | 13.80 | 19.91% | 5.25% | 12.19% | 22.36% | |
53 Neutral | AU$7.47M | 0.27 | 64.70% | ― | -24.22% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$12.59M | -2.84 | -9.80% | 10.53% | 5.74% | -222.22% | |
46 Neutral | AU$55.47M | -15.22 | -1.67% | ― | 15.21% | -141.82% | |
43 Neutral | AU$2.72M | -0.69 | -50.35% | ― | -4.87% | -9.78% | |
39 Underperform | AU$22.10M | -5.07 | 4388.00% | ― | -19.73% | 50.34% |
* Healthcare Sector Average
AU:EXL
Elixinol Wellness
0.02
<0.01
15.38%
AU:CAN
Cann Group
0.01
>-0.01
-28.57%
AU:VLS
Vita Life Sciences Limited
2.76
0.46
20.16%
AU:LGP
Little Green Pharma Ltd.
0.07
-0.07
-50.00%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-15.79%
AU:VIT
Cronos Australia Ltd.
0.02
-0.05
-71.21%
Elixinol Wellness Corporate Events
Elixinol Wellness Plans Major ASX Share Placement
Sep 24, 2026
Elixinol Wellness Limited has notified the ASX of a proposed equity issue via placement or similar mechanism, involving up to 666,666,666 ordinary fully paid shares. The proposed issue date is set for 7 December 2026, with the company agreeing to ...
Elixinol Wellness Moves to Acquire Data-Rich Platform Vitable
Sep 24, 2026
Elixinol Wellness Limited, listed on the ASX under ticker EXL, operates in the consumer wellness and health products sector. The company focuses on everyday wellness solutions and distributes its products through retail, wholesale and direct-to-co...
Elixinol to Buy Vitable in Bid to Build Scaled Wellness Platform
Sep 23, 2026
Elixinol Wellness has agreed to acquire Australian personalised supplement subscription business Vitable, adding more than $5 million in revenue and taking its annual turnover above $20 million. The deal, paid in EXL shares with a largely performa...
Elixinol Wellness Tightens Governance After Late ASX Director Interest Filing
Sep 21, 2026
Elixinol Wellness has disclosed that a Change of Director’s Interest Notice for CEO and Executive Director Natalie Butler was lodged with the ASX later than required under listing rules. The delay related to the sale of a small parcel of But...
Elixinol Wellness Converts Convertible Notes into Equity Under Cleansing Notice
Sep 16, 2026
Elixinol Wellness has issued 15,913,534 fully paid ordinary shares following the conversion of 100,000 convertible notes at a set price under its previously approved Convertible Note Facility. The issuance was carried out without a prospectus unde...
Elixinol Wellness Seeks ASX Quotation for 15.9 Million New Shares
Sep 16, 2026
Elixinol Wellness Limited has applied to the ASX for quotation of 15,913,534 new ordinary fully paid shares, to be issued and listed under its existing EXL ticker on September 17, 2026. This move increases the total number of quoted securities on ...
Elixinol Wellness Completes U.S. Exit to Focus on Australian Wellness Platform
Sep 7, 2026
Elixinol Wellness has provided a business update alongside confirmation of the completion of its U.S. divestment, signalling a strategic shift toward its Australian nutrition and wellness operations. The update, based on audited interim financial ...
Elixinol Wellness Completes Sale of U.S. Business to Refocus on Australia
Sep 7, 2026
Elixinol Wellness Limited has completed the divestment of its United States business to Ananda Health Inc., finalising a sale that delivers headline consideration of about A$465,000 through a mix of upfront, deferred and contingent payments. The t...
Elixinol Wellness Boosts Equity Base with Convertible Note Conversion
Sep 3, 2026
Elixinol Wellness has issued 24,210,906 fully paid ordinary shares following the conversion of 135,000 convertible notes at a price of $0.005576 per share, in line with a previously approved convertible note facility. The company confirmed the sha...
Elixinol seeks ASX quotation for 24.2 million new shares
Sep 3, 2026
Elixinol Wellness Limited has applied to the ASX for quotation of 24,210,906 new ordinary fully paid shares, with an issue date of 3 September 2026. The move increases the number of Elixinol securities on issue and may influence the company’...
Elixinol Wellness Narrows Loss and Reshapes Portfolio With US Exit
Aug 31, 2026
Elixinol Wellness reported a significantly improved operating performance in the first half of FY26, with revenue from continuing operations rising 5.8% to $7.2 million and gross margin expanding to 43% from 33%. Operating expenses fell 25% to $3....
Elixinol Wellness Narrows Half-Year Loss Amid Ongoing Balance Sheet Strain
Aug 31, 2026
Elixinol Wellness reported a modest 2.2% increase in revenue to $7.8 million for the half-year to 30 June 2026, while cutting its after-tax loss by 65.4% to $1.1 million. The group’s basic and diluted loss per share narrowed to 0.26 cents, r...
Elixinol Wellness Issues Over 1 Million New Convertible Notes
Aug 31, 2026
Elixinol Wellness Limited has notified the market of the issue of new unquoted convertible notes. The company will issue 1,055,800 convertible notes, documented as a new class of securities, with an issue date of 26 August 2026.The move adds to El...
Elixinol Wellness to Exit U.S. Hemp Business in A$465,000 Deal
Aug 31, 2026
Elixinol Wellness has agreed to divest its U.S. business to Ananda Health, Inc. in a binding asset sale valued at up to A$465,000, structured with upfront payments, deferred consideration, a regulatory contingent amount and a revenue-based earn-ou...
Elixinol Wellness Builds Margin-Strong Platform for Growth
Aug 7, 2026
Elixinol Wellness, trading on the ASX as EXL, is a functional nutrition and everyday wellness company focused on healthy ageing and metabolic health. It distributes products through Priceline, major grocery outlets, ecommerce and B2B partners, and...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.